{"id":"https://openalex.org/W4361944853","doi":"https://doi.org/10.1158/1078-0432.c.6522978","title":"Data from First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors","display_name":"Data from First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361944853","doi":"https://doi.org/10.1158/1078-0432.c.6522978"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.6522978","doi":"https://doi.org/10.1158/1078-0432.c.6522978","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6522978","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.c.6522978","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5045419282","display_name":"Geoffrey Ira Shapiro","orcid":"https://orcid.org/0000-0002-3331-4095","observed_orcids":["https://orcid.org/0000-0002-3331-4095"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Geoffrey I. Shapiro","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108626576","display_name":"Eunice Lee Kwak","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eunice Kwak","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109548084","display_name":"Bruce Jeffrey Dezube","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bruce J. Dezube","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067330530","display_name":"Murray Yule","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Murray Yule","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019823839","display_name":"John Ayrton","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John Ayrton","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"John Lyons","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John Lyons","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5101638085","display_name":"Daruka Mahadevan","orcid":"https://orcid.org/0000-0002-7129-5593","observed_orcids":["https://orcid.org/0000-0002-7129-5593"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daruka Mahadevan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10934","display_name":"Heat shock proteins research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10934","display_name":"Heat shock proteins research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10958","display_name":"Ultrasound and Hyperthermia Applications","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2204","display_name":"Biomedical Engineering"},"field":{"id":"https://openalex.org/fields/22","display_name":"Engineering"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/at13387","display_name":"AT13387","score":1.0},{"id":"https://openalex.org/keywords/hsp90-inhibitors","display_name":"Hsp90 inhibitors","score":0.9459999799728394},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.8140000104904175},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7639999985694885},{"id":"https://openalex.org/keywords/recommended-phase-ii-dose","display_name":"recommended phase 2 dose","score":0.9290000200271606},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9639999866485596},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9629999995231628},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9279999732971191},{"id":"https://openalex.org/keywords/hsp70-induction","display_name":"HSP70 induction","score":0.9959999918937683},{"id":"https://openalex.org/keywords/target-engagement","display_name":"target engagement","score":0.9049999713897705},{"id":"https://openalex.org/keywords/gastrointestinal-stromal-tumor","display_name":"gastrointestinal stromal tumor","score":0.9430000185966492},{"id":"https://openalex.org/keywords/imatinib-refractory-disease","display_name":"imatinib-refractory disease","score":0.8019999861717224},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.8270000219345093},{"id":"https://openalex.org/keywords/safety-profile","display_name":"safety profile","score":0.44699999690055847}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7120749950408936},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6712201833724976},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.587329089641571},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.5600830316543579},{"id":"https://openalex.org/C2780852908","wikidata":"https://www.wikidata.org/wiki/Q127076","display_name":"Vomiting","level":2,"score":0.5171348452568054},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.504407525062561},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.49705246090888977},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4766177237033844},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.466098427772522},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.44977235794067383},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3663368821144104},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.c.6522978","doi":"https://doi.org/10.1158/1078-0432.c.6522978","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6522978","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.6522978","doi":"https://doi.org/10.1158/1078-0432.c.6522978","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.6522978","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2151252337","https://openalex.org/W2754632478","https://openalex.org/W2602346810","https://openalex.org/W2329550233","https://openalex.org/W2336736232","https://openalex.org/W612504614","https://openalex.org/W2397217268","https://openalex.org/W2113312886","https://openalex.org/W2911547717","https://openalex.org/W2334958964"],"abstract_inverted_index":{"Abstract":[0],"Purpose:":[1],"AT13387":[2,32,172,229],"is":[3],"a":[4,35,205],"potent":[5],"second-generation,":[6],"fragment-derived":[7],"HSP90":[8],"inhibitor.":[9],"This":[10],"phase":[11,20],"I":[12],"study":[13],"investigated":[14],"the":[15,55,131,136,144,168],"maximum":[16],"tolerated":[17],"dose":[18,22,44],"(MTD)/recommended":[19],"II":[21],"(RP2D)":[23],"and":[24,27,49,61,71,86,105,133,157,187,208,240,246],"safety,":[25],"pharmacokinetic,":[26],"pharmacodynamic":[28],"profiles":[29],"of":[30,57,76,121,164,171,243],"two":[31],"regimens":[33],"in":[34,80,143,185,225],"refractory":[36],"solid":[37],"tumor":[38,88,188,196],"population.":[39],"Experimental":[40],"Design:":[41],"Standard":[42],"3+3":[43],"escalation":[45],"was":[46,78,129],"used.":[47],"MTD":[48,132],"RP2D":[50,134],"determinations":[51],"were":[52,67,93],"based":[53],"on":[54,202,210],"occurrence":[56],"dose-limiting":[58],"toxicities":[59],"(DLT)":[60],"overall":[62],"toxicity,":[63],"respectively.":[64],"Pharmacokinetic":[65],"parameters":[66],"measured":[68,180],"after":[69],"single":[70],"multiple":[72,148],"doses.":[73],"AT13387-mediated":[74],"induction":[75,183],"HSP70":[77,182],"evaluated":[79],"plasma,":[81],"peripheral":[82],"blood":[83],"mononuclear":[84],"cells,":[85],"paired":[87],"biopsies.":[89],"Results:":[90],"Sixty-two":[91],"patients":[92,216],"treated":[94],"with":[95,175,193],"doses":[96],"ranging":[97],"from":[98],"10":[99,213],"to":[100,107,162],"120":[101,126],"mg/m2":[102,109,166],"twice":[103,233],"weekly":[104,111,234],"150":[106],"310":[108],"once":[110,231],"(both":[112],"for":[113,135,212],"3":[114],"weeks":[115],"every":[116],"28":[117],"days).":[118],"One":[119,191],"DLT":[120],"visual":[122],"disturbance":[123],"occurred":[124,142,184],"at":[125],"mg/m2,":[127],"which":[128,221],"considered":[130],"twice-weekly":[137],"regimen.":[138],"No":[139],"formal":[140],"DLTs":[141],"once-weekly":[145],"regimen,":[146],"but":[147],"moderately":[149],"severe":[150],"toxicities,":[151],"including":[152],"diarrhea,":[153],"nausea,":[154],"vomiting,":[155],"fatigue,":[156],"systemic":[158],"infusion":[159],"reactions,":[160],"led":[161],"selection":[163],"260":[165],"as":[167,179],"RP2D.":[169],"Exposures":[170],"increased":[173],"proportionally":[174],"dose.":[176],"Target":[177],"engagement":[178,245],"by":[181],"plasma":[186],"biopsy":[189],"samples.":[190],"patient":[192],"gastrointestinal":[194],"stromal":[195],"(GIST)":[197],"who":[198],"had":[199,204,218],"progressive":[200],"disease":[201],"imatinib":[203],"partial":[206],"response":[207],"remained":[209],"treatment":[211],"months.":[214],"Twenty-one":[215],"(34%)":[217],"stable":[219],"disease,":[220],"lasted":[222],">120":[223],"days":[224],"7":[226],"patients.":[227],"Conclusion:":[228],"administered":[230],"or":[232],"has":[235],"an":[236],"acceptable":[237],"safety":[238],"profile":[239],"demonstrated":[241],"evidence":[242],"target":[244],"preliminary":[247],"antitumor":[248],"activity.":[249],"Clin":[250],"Cancer":[251],"Res;":[252],"21(1);":[253],"87\u201397.":[254],"\u00a92014":[255],"AACR.":[256]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2023-04-05T00:00:00"}